Last reviewed · How we verify
bitopertin [RO4917838] level 1
Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases synaptic glycine levels to enhance NMDA receptor function in the brain.
Bitopertin is a glycine transporter 1 (GlyT1) inhibitor that increases synaptic glycine levels to enhance NMDA receptor function in the brain. Used for Schizophrenia (negative and cognitive symptoms, as adjunctive therapy), Autism spectrum disorder (investigational).
At a glance
| Generic name | bitopertin [RO4917838] level 1 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Glycine transporter 1 (GlyT1) inhibitor |
| Target | GlyT1 (SLC6A9) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
By blocking the reuptake of glycine at the presynaptic terminal, bitopertin increases glycine concentration in the synaptic cleft. Glycine acts as a co-agonist at NMDA receptors, and elevated levels potentiate glutamatergic neurotransmission, which is hypothesized to improve cognitive and negative symptoms in schizophrenia and other neuropsychiatric disorders.
Approved indications
- Schizophrenia (negative and cognitive symptoms, as adjunctive therapy)
- Autism spectrum disorder (investigational)
Common side effects
- Headache
- Dizziness
- Nausea
- Insomnia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bitopertin [RO4917838] level 1 CI brief — competitive landscape report
- bitopertin [RO4917838] level 1 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI